A Phase 3 interventional study of Daprodustat and Darbepoetin alfa in Anaemia, sponsored by GlaxoSmithKline. Completed at 578 sites in 39 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one has the largest enrollment, is one of 5 that started in 2016, is one of 9 in phase 3, and was the 16th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,872 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one has the largest enrollment, is one of 6 that started in 2016, is one of 10 in phase 3, and was the 21st registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral daprodustat once daily.
Drug: Daprodustat · Drug: Placebo · Drug: Iron Therapy
Participants will be administered darbepoetin alfa subcutaneously (SC).
Drug: Darbepoetin alfa · Drug: Placebo · Drug: Iron Therapy
The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)
Time to MACE defined as time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, current erythropoiesis-stimulating agents (ESA) use at randomization and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 person years calculated as (100 multiplied \[\*\] number of participants with at least 1 event) divided by \[/\] first event person-years) is presented along with 95 percent (%) confidence interval (CI). First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)
Blood samples were collected from participants for Hgb measurements. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputation methods. Change from Baseline was defined as post-Baseline value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using the Analysis of covariance (ANCOVA) model with terms for treatment, Baseline Hgb, current ESA use and region.
Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)
Time to MACE defined as the time to first occurrence of CEC adjudicated MACE was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariate. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period
Time to first occurrence of adjudicated MACE or thromboembolic event (vascular access thrombosis, symptomatic deep vein thrombosis or symptomatic pulmonary embolism) was analyzed using a Cox proportional hazards regression model with with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period
Time to first occurrence of adjudicated MACE or hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period
Progression of CKD defined as: 40% decline in estimated glomerular filtration rate (eGFR) from Baseline or end stage renal disease (ESRD) as defined by either initiating chronic dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated or kidney transplantation. Time to first occurrence of CKD progression was analyzed using Fine and Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) +1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period
Time to first occurrence of adjudicated all-cause mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the vital status follow-up time period.
Time frame: Up to 4.3 person-years for vital status follow-up time period
Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period
Time to first occurrence of adjudicated CV mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Time to first occurrence of adjudicated MI (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Time to first occurrence of adjudicated stroke (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)
Number of participants with adjudicated MACE or hospitalization for heart failure (recurrent events analysis) is presented, categorized by number of occurrences of adjudicated MACE or hospitalization for heart failure per participant.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period
Time to first occurrence of adjudicated CV mortality or non-fatal MI was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period
All-cause hospitalization events were hospital admissions recorded on the hospitalization electronic case report form (eCRF) form with a hospitalization duration \>=24 hours. Time to first occurrence of all-cause hospitalization was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period
All-cause hospital re-admissions within 30days are defined as hospital admissions recorded on hospitalization electronic case record form with hospitalization duration of \>=24 hours and admission date within 30days following previous discharge date of all-cause hospitalization event, where previous hospitalization was \>=24hours.Time to first occurrence of all-cause hospital re-admission within 30days was analyzed using Cox proportional hazards regression model with treatment group, current ESA use at randomization and region as covariates.Time to the first occurrence was computed as(event date - randomization date)+1. Incidence rate per 100 person years calculated as(100\*number of participants with at least 1event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period
Time to first occurrence of adjudicated MACE or hospitalization for heart failure or thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period
Time to first occurrence of adjudicated hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period
Time to first occurrence of adjudicated thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period
Time to first occurrence of confirmed 40% decline in eGFR was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period
Time to first occurrence of chronic dialysis was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Chronic dialysis is defined by either initiating dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Time to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period
Time to first occurrence of kidney transplant were analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
Time frame: Up to 4.3 person-years for CV follow-up time period
Change From Baseline in Post-randomization Hgb Levels at Week 52
Blood samples were collected from participants for Hgb measurements. Change from Baseline was defined as post-randomization value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using mixed model repeated measures (MMRM) model fitted from Baseline up to Week 52, excluding values collected during the stabilization period, with factors for treatment, time, current ESA use, region, Baseline Hgb and Baseline Hgb by time and treatment by time interactions.
Time frame: Baseline (Pre-dose on Day 1) and Week 52
Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)
Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.
Time frame: Week 28 to Week 52
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].
Time frame: Week 28 to Week 52
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].
Time frame: Week 28 to Week 52
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].
Time frame: Week 28 to end of study (4.3 person-years for follow-up time period)
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].
Time frame: Week 28 to end of study (4.3 person-years for follow-up time period)
Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52
SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is the average (BP) in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using MMRM model with treatment group + time + current ESA use at randomization + region + Baseline value + Baseline value\*time + treatment group\*time, using an unstructured covariance matrix. Data for post-dialysis BP measurements have been presented.
Time frame: Baseline (Week -4) and Week 52
Change From Baseline in SBP, DBP, MAP at End of Treatment
SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using ANCOVA model with terms for treatment group, current ESA use at randomization, region and Baseline value. Data for post-dialysis BP measurements have been presented.
Time frame: Baseline (Week -4) and 51.1 months
Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years
BP exacerbation event (based on post-dialysis) was defined as: SBP \>= 25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the negative binomial model with treatment, current ESA use at randomization and region as covariates and the logarithm of time on-treatment as an offset variable. Data for post-dialysis BP measurements have been presented.
Time frame: Day 1 to end of treatment (51.1 months)
Number of Participants With at Least One BP Exacerbation Event During Study
BP exacerbation was defined as: SBP \>= 25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one BP exacerbation event is presented.
Time frame: Day 1 to end of treatment (51.1 months)
Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria
Percentage of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.
Time frame: Day 1 to 51.1 months
Change From Baseline in On-treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher score represents better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in On-treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in On-treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain (b pain), general health (GH), mental health (MH), role-emotional (RE) (role limitations caused by emotional problems), role-physical (RP) (role limitations caused by physical problems), social functioning (SF), physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline (BL) was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in On-treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in On-treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52
EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health state). Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.
Time frame: Baseline (Pre-dose on Day 1) and Week 52
Change From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52
The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst imaginable health and 100 represents the best imaginable health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1) and Week 52
Change From Baseline in On-treatment Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Weeks 8, 12, 28, 52
CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy (LE)/Weak scale consisting of 10 items; 2.Chest Pain (CP)/Shortness of Breath (SOB) scale consisting of 4 items; and 3.Cognitive (Cog) scale consisting of 3 items. The 4 CKD-AQ single items are: shortness of breath, no activity; severity-short breath (S-SB), resting; difficulty standing (diff. std.)for long time (LT) and difficulty sleeping (diff sleep). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1) and Weeks 8, 12, 28, 52
Change From Baseline in On-treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52
The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated more disease severity. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52
Blood samples were collected to analyze estimated glomerular filtration rate. Change from Baseline was calculated as post-Baseline visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Pre-dose on Day 1) and Week 52
This was a multicenter study conducted across 39 countries. Participants were randomized to receive either daprodustat or darbepoetin alfa.
| Milestone | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Started | 1937 | 1935 |
| Completed | 1937 | 1935 |
| Not completed | 0 | 0 |
| Milestone | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Started | 1937 | 1935 |
| Completed | 1873 | 1870 |
| Not completed | 64 | 65 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Investigator site closed | 6 | 13 |
| Withdrew: Withdrawal by subject | 32 | 23 |
| Withdrew: Lost to follow-up | 25 | 29 |
Time to MACE defined as time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, current erythropoiesis-stimulating agents (ESA) use at randomization and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 person years calculated as (100 multiplied \[\*\] number of participants with at least 1 event) divided by \[/\] first event person-years) is presented along with 95 percent (%) confidence interval (CI). First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis) | 10.86 (9.80 to 12.02) | 10.63 (9.58 to 11.77) |
Blood samples were collected from participants for Hgb measurements. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputation methods. Change from Baseline was defined as post-Baseline value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using the Analysis of covariance (ANCOVA) model with terms for treatment, Baseline Hgb, current ESA use and region.
| Grams per deciliter | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52) | 0.74 ± 0.019 | 0.66 ± 0.019 |
Time to MACE defined as the time to first occurrence of CEC adjudicated MACE was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariate. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis) | 10.86 (9.80 to 12.02) | 10.63 (9.58 to 11.77) |
Time to first occurrence of adjudicated MACE or thromboembolic event (vascular access thrombosis, symptomatic deep vein thrombosis or symptomatic pulmonary embolism) was analyzed using a Cox proportional hazards regression model with with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period | 12.34 (11.19 to 13.57) | 11.77 (10.65 to 12.98) |
Time to first occurrence of adjudicated MACE or hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period | 13.16 (11.97 to 14.44) | 12.22 (11.08 to 13.46) |
Progression of CKD defined as: 40% decline in estimated glomerular filtration rate (eGFR) from Baseline or end stage renal disease (ESRD) as defined by either initiating chronic dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated or kidney transplantation. Time to first occurrence of CKD progression was analyzed using Fine and Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) +1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period | 17.55 (15.74 to 19.51) | 17.76 (15.97 to 19.70) |
Time to first occurrence of adjudicated all-cause mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the vital status follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period | 8.35 (7.43 to 9.35) | 8.27 (7.35 to 9.26) |
Time to first occurrence of adjudicated CV mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period | 3.02 (2.48 to 3.65) | 2.55 (2.06 to 3.13) |
Time to first occurrence of adjudicated MI (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period | 2.94 (2.40 to 3.56) | 2.76 (2.24 to 3.36) |
Time to first occurrence of adjudicated stroke (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period | 1.26 (0.92 to 1.69) | 0.95 (0.66 to 1.33) |
Number of participants with adjudicated MACE or hospitalization for heart failure (recurrent events analysis) is presented, categorized by number of occurrences of adjudicated MACE or hospitalization for heart failure per participant.
| Participants | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Occurrences per participant: 0 | 1493 | 1518 |
| Occurrences per participant: 1 | 318 | 317 |
| Occurrences per participant: 2 | 76 | 64 |
| Occurrences per participant: 3 | 26 | 22 |
| Occurrences per participant: 4 | 14 | 9 |
| Occurrences per participant: 5 | 5 | 3 |
| Occurrences per participant: 6 | 1 | 0 |
| Occurrences per participant: 7 | 4 | 1 |
| Occurrences per participant: 8 | 0 | 1 |
Time to first occurrence of adjudicated CV mortality or non-fatal MI was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period | 5.36 (4.62 to 6.18) | 4.98 (4.27 to 5.77) |
All-cause hospitalization events were hospital admissions recorded on the hospitalization electronic case report form (eCRF) form with a hospitalization duration \>=24 hours. Time to first occurrence of all-cause hospitalization was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period | 41.13 (38.59 to 43.80) | 38.99 (36.54 to 41.56) |
All-cause hospital re-admissions within 30days are defined as hospital admissions recorded on hospitalization electronic case record form with hospitalization duration of \>=24 hours and admission date within 30days following previous discharge date of all-cause hospitalization event, where previous hospitalization was \>=24hours.Time to first occurrence of all-cause hospital re-admission within 30days was analyzed using Cox proportional hazards regression model with treatment group, current ESA use at randomization and region as covariates.Time to the first occurrence was computed as(event date - randomization date)+1. Incidence rate per 100 person years calculated as(100\*number of participants with at least 1event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period | 7.78 (6.87 to 8.79) | 7.55 (6.65 to 8.55) |
Time to first occurrence of adjudicated MACE or hospitalization for heart failure or thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period | 14.60 (13.33 to 15.96) | 13.32 (12.11 to 14.61) |
Time to first occurrence of adjudicated hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period | 4.05 (3.41 to 4.78) | 3.30 (2.73 to 3.96) |
Time to first occurrence of adjudicated thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period | 1.81 (1.39 to 2.31) | 1.43 (1.07 to 1.89) |
Time to first occurrence of confirmed 40% decline in eGFR was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period | 8.21 (7.04 to 9.52) | 8.90 (7.69 to 10.24) |
Time to first occurrence of chronic dialysis was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Chronic dialysis is defined by either initiating dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period | 12.20 (10.74 to 13.81) | 12.06 (10.63 to 13.62) |
Time to first occurrence of kidney transplant were analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.
| Events per 100 person years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Time to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period | 1.00 (0.63 to 1.50) | 1.14 (0.75 to 1.66) |
Blood samples were collected from participants for Hgb measurements. Change from Baseline was defined as post-randomization value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using mixed model repeated measures (MMRM) model fitted from Baseline up to Week 52, excluding values collected during the stabilization period, with factors for treatment, time, current ESA use, region, Baseline Hgb and Baseline Hgb by time and treatment by time interactions.
| Grams per deciliter | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Change From Baseline in Post-randomization Hgb Levels at Week 52 | 0.76 ± 0.029 | 0.73 ± 0.029 |
Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.
| Participants | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52) | 1167 | 1063 |
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].
| Percentage of days | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis | 70.5 (0.0 to 100.0) | 63.2 (0.0 to 100.0) |
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].
| Percentage of days | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis | 70.5 (0.0 to 100.0) | 63.2 (0.0 to 100.0) |
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].
| Percentage of days | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis | 66.1 (0.0 to 100.0) | 62.1 (0.0 to 100.0) |
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].
| Percentage of days | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis | 66.1 (0.0 to 100.0) | 62.1 (0.0 to 100.0) |
SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is the average (BP) in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using MMRM model with treatment group + time + current ESA use at randomization + region + Baseline value + Baseline value\*time + treatment group\*time, using an unstructured covariance matrix. Data for post-dialysis BP measurements have been presented.
| Millimeter of mercury | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| SBP, n=1913, 1884 | -0.62 ± 0.488 | -1.17 ± 0.479 |
| DBP, n=1912, 1884 | 0.06 ± 0.267 | -0.59 ± 0.262 |
| MAP, n=1912, 1884 | -0.17 ± 0.300 | -0.77 ± 0.294 |
SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using ANCOVA model with terms for treatment group, current ESA use at randomization, region and Baseline value. Data for post-dialysis BP measurements have been presented.
| Millimeter of mercury | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| SBP, n=1919, 1884 | -1.19 ± 0.395 | -1.10 ± 0.398 |
| DBP, n=1918, 1884 | -0.26 ± 0.229 | -0.38 ± 0.231 |
| MAP, n=1918, 1884 | -0.57 ± 0.248 | -0.62 ± 0.251 |
BP exacerbation event (based on post-dialysis) was defined as: SBP \>= 25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the negative binomial model with treatment, current ESA use at randomization and region as covariates and the logarithm of time on-treatment as an offset variable. Data for post-dialysis BP measurements have been presented.
| Events per 100 participant years | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years | 138.50 (128.58 to 149.18) | 157.35 (146.30 to 169.23) |
BP exacerbation was defined as: SBP \>= 25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one BP exacerbation event is presented.
| Participants | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Number of Participants With at Least One BP Exacerbation Event During Study | 939 | 1012 |
Percentage of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.
| Percentage of participants | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria | 2.0 | 3.3 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher score represents better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=1238,1187 | 0.42 ± 0.169 | 0.78 ± 0.172 |
| Week 12, n=1237,1227 | 0.60 ± 0.171 | 0.71 ± 0.172 |
| Week 28, n=968,956 | 0.16 ± 0.197 | 0.04 ± 0.198 |
| Week 52, n=804,780 | -0.32 ± 0.218 | -0.12 ± 0.221 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=1238,1187 | 0.08 ± 0.217 | 0.37 ± 0.221 |
| Week 12, n=1237,1227 | 0.02 ± 0.223 | 0.18 ± 0.224 |
| Week 28, n=968,956 | -0.35 ± 0.244 | -0.02 ± 0.245 |
| Week 52, n=804,780 | -0.71 ± 0.290 | -0.35 ± 0.294 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain (b pain), general health (GH), mental health (MH), role-emotional (RE) (role limitations caused by emotional problems), role-physical (RP) (role limitations caused by physical problems), social functioning (SF), physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline (BL) was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Bodily pain: Week 8, n=1238,1187 | 0.11 ± 0.221 | 0.45 ± 0.225 |
| Bodily pain: Week 12, n=1237,1227 | 0.35 ± 0.223 | 0.50 ± 0.224 |
| Bodily pain: Week 28, n=968,956 | -0.48 ± 0.261 | 0.02 ± 0.263 |
| Bodily pain: Week 52, n=804,780 | -0.34 ± 0.283 | 0.13 ± 0.288 |
| General health: Week 8, n=1238,1187 | 0.36 ± 0.171 | 0.43 ± 0.174 |
| General health: Week 12, n=1237,1227 | 0.28 ± 0.174 | 0.48 ± 0.175 |
| General health: Week 28, n=968,956 | 0.14 ± 0.200 | 0.04 ± 0.201 |
| General health: Week 52, n=804,780 | -0.27 ± 0.220 | -0.19 ± 0.224 |
| Mental health: Week 8, n=1238,1187 | -0.19 ± 0.204 | 0.12 ± 0.208 |
| Mental health: Week 12, n=1237,1227 | -0.07 ± 0.210 | -0.09 ± 0.211 |
| Mental health: Week 28, n=968,956 | -0.67 ± 0.231 | -0.37 ± 0.232 |
| Mental health: Week 52, n=804,780 | -0.85 ± 0.271 | -0.61 ± 0.275 |
| Role-emotional: Week 8, n=1238,1187 | 0.45 ± 0.253 | 0.54 ± 0.258 |
| Role-emotional: Week 12, n=1237,1227 | 0.17 ± 0.258 | 0.43 ± 0.259 |
| Role-emotional: Week 28, n=968,956 | -0.30 ± 0.290 | 0.07 ± 0.292 |
| Role-emotional: Week 52, n=804,780 | -0.90 ± 0.339 | -0.38 ± 0.344 |
| Role-physical: Week 8, n=1238,1187 | 0.33 ± 0.202 | 0.83 ± 0.205 |
| Role-physical: Week 12, n=1237,1227 | 0.40 ± 0.203 | 0.73 ± 0.204 |
| Role-physical: Week 28, n=968,956 | 0.06 ± 0.230 | 0.00 ± 0.232 |
| Role-physical: Week 52, n=804,780 | -0.63 ± 0.259 | -0.44 ± 0.263 |
| Social functioning: Week 8, n=1238,1187 | 0.19 ± 0.224 | 0.82 ± 0.228 |
| Social functioning: Week 12, n=1237,1227 | 0.21 ± 0.224 | 0.53 ± 0.225 |
| Social functioning: Week 28, n=968,956 | 0.04 ± 0.247 | 0.17 ± 0.249 |
| Social functioning: Week 52, n=804,780 | -0.58 ± 0.282 | -0.20 ± 0.286 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=1238,1187 | 0.35 ± 0.192 | 0.90 ± 0.195 |
| Week 12, n=1237,1227 | 0.62 ± 0.200 | 0.74 ± 0.201 |
| Week 28, n=968,956 | 0.22 ± 0.222 | 0.32 ± 0.223 |
| Week 52, n=804,780 | -0.14 ± 0.250 | 0.35 ± 0.253 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=1238,1187 | 0.51 ± 0.200 | 0.83 ± 0.203 |
| Week 12, n=1237,1227 | 0.65 ± 0.195 | 0.52 ± 0.196 |
| Week 28, n=968,956 | 0.05 ± 0.224 | -0.10 ± 0.225 |
| Week 52, n=804,780 | -0.69 ± 0.262 | -0.37 ± 0.266 |
EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health state). Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Change From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52 | -0.0253 ± 0.00842 | -0.0018 ± 0.00883 |
The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst imaginable health and 100 represents the best imaginable health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Change From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52 | -0.7 ± 0.78 | -1.4 ± 0.82 |
CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy (LE)/Weak scale consisting of 10 items; 2.Chest Pain (CP)/Shortness of Breath (SOB) scale consisting of 4 items; and 3.Cognitive (Cog) scale consisting of 3 items. The 4 CKD-AQ single items are: shortness of breath, no activity; severity-short breath (S-SB), resting; difficulty standing (diff. std.)for long time (LT) and difficulty sleeping (diff sleep). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Tired/Low energy/Weak domain: Week 8,n=1340,1294 | 1.72 ± 0.424 | 2.94 ± 0.429 |
| Tired/Low energy/Weak domain: Week 12,n=1341,1360 | 2.11 ± 0.437 | 3.08 ± 0.434 |
| Tired/Low energy/Weak domain: Week 28,n=1053,1047 | 1.27 ± 0.495 | 1.87 ± 0.496 |
| Tired/Low energy/Weak domain: Week 52,n=870,865 | 0.20 ± 0.554 | 1.77 ± 0.556 |
| Chest pain/SOB domain: Week 8,n=1340,1294 | 0.63 ± 0.358 | 1.83 ± 0.363 |
| Chest pain/ SOB domain: Week 12,n=1341,1360 | 0.88 ± 0.370 | 1.53 ± 0.368 |
| Chest pain/ SOB domain: Week 28,n=1053,1047 | 0.01 ± 0.424 | 0.53 ± 0.425 |
| Chest pain/ SOB domain: Week 52,n=870,865 | -0.71 ± 0.471 | 0.47 ± 0.473 |
| Cognitive domain: Week 8,n=1340,1294 | 0.13 ± 0.413 | 0.89 ± 0.419 |
| Cognitive domain: Week 12,n=1341,1360 | -0.17 ± 0.414 | 1.01 ± 0.412 |
| Cognitive domain: Week 28,n=1053,1047 | -0.40 ± 0.468 | 0.37 ± 0.469 |
| Cognitive domain: Week 52,n=870,865 | -2.00 ± 0.526 | -0.35 ± 0.527 |
| SOB, no activity: Week 8,n=1340,1294 | -0.1 ± 0.42 | 1.0 ± 0.42 |
| SOB, no activity: Week 12,n=1341,1360 | 0.1 ± 0.43 | 0.4 ± 0.42 |
| SOB, no activity: Week 28,n=1053,1047 | -1.1 ± 0.50 | -0.2 ± 0.50 |
| SOB, no activity: Week 52,n=870,865 | -1.7 ± 0.57 | -1.6 ± 0.57 |
| Severity-short breath, Resting: Week 8,n=1340,1294 | -0.3 ± 0.40 | 0.8 ± 0.40 |
| Severity-short breath, Resting:Week 12,n=1341,1360 | -0.3 ± 0.42 | 0.0 ± 0.42 |
| Severity-short breath, Resting:Week 28,n=1053,1047 | -1.1 ± 0.48 | -0.7 ± 0.48 |
| Severity-short breath, Resting:Week 52,n=870,865 | -2.0 ± 0.53 | -0.5 ± 0.53 |
| Diff std for long time: Week 8,n=1340,1294 | 1.0 ± 0.62 | 2.5 ± 0.63 |
| Diff std for long time: Week 12,n=1341,1360 | 0.7 ± 0.63 | 1.6 ± 0.62 |
| Diff std for long time: Week 28,n=1053,1047 | 0.4 ± 0.71 | 1.7 ± 0.71 |
| Diff std for long time: Week 52,n=870,865 | -2.1 ± 0.76 | 1.2 ± 0.76 |
| Difficulty sleeping: Week 8,n=1340,1294 | 1.6 ± 0.60 | 1.1 ± 0.61 |
| Difficulty sleeping: Week 12,n=1341,1360 | 0.5 ± 0.60 | 2.0 ± 0.59 |
| Difficulty sleeping: Week 28,n=1053,1047 | -0.7 ± 0.69 | -0.3 ± 0.70 |
| Difficulty sleeping: Week 52,n=870,865 | -2.6 ± 0.78 | -0.3 ± 0.78 |
The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated more disease severity. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=1341,1295 | 0.00 ± 0.022 | -0.02 ± 0.022 |
| Week 12, n=1341,1362 | 0.03 ± 0.022 | -0.02 ± 0.022 |
| Week 28, n=1054,1051 | 0.05 ± 0.025 | 0.09 ± 0.025 |
| Week 52, n=871,865 | 0.11 ± 0.028 | 0.06 ± 0.029 |
Blood samples were collected to analyze estimated glomerular filtration rate. Change from Baseline was calculated as post-Baseline visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| mL per minute per 1.73 square meter | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Change From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52 | -2.88 ± 0.193 | -2.67 ± 0.193 |
Collected over All-cause mortality, serious adverse events (SAEs) and non-SAEs were collected from Week -4 up to randomization (Day 1) during Run-in placebo period. All-cause mortality, treatment emergent serious adverse events (TESAEs) and non-serious treatment emergent adverse events (non-STEAEs) were collected from randomization (Day 1) up to 4.3 person-years for CV follow-up time period (Treatment Period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Period: Placebo | 0/3,872 (0%) | 63/3,872 (1.6%) | 0/3,872 (0%) |
| Daprodustat | 301/1,937 (15.5%) | 850/1,937 (43.9%) | 851/1,937 (43.9%) |
| Darbepoetin Alfa | 298/1,935 (15.4%) | 703/1,933 (36.4%) | 825/1,933 (42.7%) |
| Event | Run-in Period: Placebo | Daprodustat | Darbepoetin Alfa |
|---|---|---|---|
| Chronic kidney diseaseRenal and urinary disorders | 1/3872 | 86/1937 | 49/1933 |
| PneumoniaInfections and infestations | 3/3872 | 78/1937 | 75/1933 |
| Acute kidney injuryRenal and urinary disorders | 1/3872 | 70/1937 | 47/1933 |
| AzotaemiaRenal and urinary disorders | 1/3872 | 54/1937 | 35/1933 |
| End stage renal diseaseRenal and urinary disorders | 0/3872 | 48/1937 | 36/1933 |
| COVID-19Infections and infestations | 1/3872 | 39/1937 | 33/1933 |
| Acute myocardial infarctionCardiac disorders | 1/3872 | 37/1937 | 26/1933 |
| Urinary tract infectionInfections and infestations | 2/3872 | 33/1937 | 36/1933 |
| AnaemiaBlood and lymphatic system disorders | 3/3872 | 33/1937 | 31/1933 |
| Cardiac failure congestiveCardiac disorders | 1/3872 | 29/1937 | 20/1933 |
| Event | Run-in Period: Placebo | Daprodustat | Darbepoetin Alfa |
|---|---|---|---|
| HypertensionVascular disorders | 0/3872 | 247/1937 | 264/1933 |
| Oedema peripheralGeneral disorders | 0/3872 | 198/1937 | 162/1933 |
| Urinary tract infectionInfections and infestations | 0/3872 | 164/1937 | 153/1933 |
| DiarrhoeaGastrointestinal disorders | 0/3872 | 149/1937 | 139/1933 |
| NasopharyngitisInfections and infestations | 0/3872 | 118/1937 | 133/1933 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/3872 | 128/1937 | 122/1933 |
| ConstipationGastrointestinal disorders | 0/3872 | 127/1937 | 88/1933 |
| Back painMusculoskeletal and connective tissue disorders | 0/3872 | 82/1937 | 105/1933 |
| FallInjury, poisoning and procedural complications | 0/3872 | 104/1937 | 88/1933 |
| NauseaGastrointestinal disorders | 0/3872 | 103/1937 | 84/1933 |
All Randomized (Intent-to-treat \[ITT\]) Population comprised of all randomized participants. Participants were analyzed according to the treatment to which they were randomized.
| Age, Continuous(Years) | Daprodustat | Darbepoetin Alfa | Total |
|---|---|---|---|
| Mean | 64.8 ± 14.03 | 64.9 ± 13.83 | 64.8 ± 13.93 |
| Sex: Female, Male(Participants) | Daprodustat | Darbepoetin Alfa | Total |
|---|---|---|---|
| Female | 1102 | 1071 | 2173 |
| Male | 835 | 864 | 1699 |
| Race/Ethnicity, Customized(Participants) | Daprodustat | Darbepoetin Alfa | Total |
|---|---|---|---|
| American Indian or Alaskan Native | 88 | 100 | 188 |
| Asian - Central/South Asian Heritage | 58 | 71 | 129 |
| Asian - East Asian Heritage | 245 | 232 | 477 |
| Asian - Japanese Heritage | 5 | 3 | 8 |
| Asian - South East Asian Heritage | 216 | 229 | 445 |
| Black or African American | 183 | 185 | 368 |
| Native Hawaiian or Other Pacific Islander | 7 | 7 | 14 |
| White - Arabic/North African Heritage | 19 | 18 | 37 |
| White - White/Caucasian/European Heritage | 1079 | 1037 | 2116 |
| Mixed Asian Race | 1 | 2 | 3 |
| Mixed Race | 36 | 51 | 87 |
Showing the first 100 of 578 sites across 39 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Sep 2016 to primary completion in Apr 2021, 54 months.
Results were first posted in Apr 2022, 11 months after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 54 months is above that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863